172 related articles for article (PubMed ID: 23841569)
1. Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes.
Koehler G; Treiber G; Wutte A; Korsatko S; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2014 Jan; 16(1):57-62. PubMed ID: 23841569
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
3. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
4. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
[TBL] [Abstract][Full Text] [Related]
5. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
[TBL] [Abstract][Full Text] [Related]
7. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
10. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
11. Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.
Linnebjerg H; Lam EC; Zhang X; Seger ME; Coutant D; Chua L; Kapitza C; Heise T
Diabetes Obes Metab; 2017 Jan; 19(1):33-39. PubMed ID: 27484286
[TBL] [Abstract][Full Text] [Related]
12. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
13. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
[TBL] [Abstract][Full Text] [Related]
14. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
Becker RH; Nowotny I; Teichert L; Bergmann K; Kapitza C
Diabetes Obes Metab; 2015 Mar; 17(3):261-7. PubMed ID: 25425394
[TBL] [Abstract][Full Text] [Related]
15. LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.
Zhang X; Lam ECQ; Seger ME; Coutant D; Chua L; Tan LH; Soon D; Linnebjerg H
Clin Pharmacol Drug Dev; 2017 Nov; 6(6):556-563. PubMed ID: 28940840
[TBL] [Abstract][Full Text] [Related]
16. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.
Ocheltree SM; Hompesch M; Wondmagegnehu ET; Morrow L; Win K; Jacober SJ
Eur J Endocrinol; 2010 Aug; 163(2):217-23. PubMed ID: 20508081
[TBL] [Abstract][Full Text] [Related]
18. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
[TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
